Analysts See $-0.01 EPS for Pediapharm Inc. (PDP)

November 10, 2018 - By Jimmy Baldridge

Pediapharm Inc. (CVE:PDP) Logo

Analysts expect Pediapharm Inc. (CVE:PDP) to report $-0.01 EPS on November, 26.After having $-0.01 EPS previously, Pediapharm Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.61% or $0.005 during the last trading session, reaching $0.315. About 165,000 shares traded or 111.96% up from the average. Pediapharm Inc. (CVE:PDP) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Pediapharm Inc. operates as a specialty pharmaceutical firm in Canada. The company has market cap of $69.68 million. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children. It currently has negative earnings. The company's product portfolio includes NYDA, a product for the treatment of head lice and its eggs; Relaxa to treat constipation; and naproxen suspension to treat medical pain conditions in Juvenile Arthritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.